胃肠病学市场规模、份额、成长分析，按类型、按分销管道、按应用、按管理途径、按地区 - 行业预测，2025-2032

2023年全球胃肠病学市场规模预计为374亿美元，从2024年的626.5亿美元增长到2032年的626.5亿美元，预测期内（2025-2032年）复合年增长率为5.9%，预计将增长至2023年。

由于不良饮食习惯和老年人口增加导致胃肠道疾病盛行率不断增加，胃肠道疾病市场正在经历显着增长。胃肠道疾病的快速增加导致住院和手术的增加，主要企业正在加紧生技药品和生物相似药的研发。此外，临床试验的扩大，截至 2021 年 5 月正在进行 6,443 项临床试验，展示了包括细胞疗法和小分子在内的创新治疗的强大管道。随着医疗保健领域的发展，这些发展为有效治疗方法提供了新的机会，并进一步支持未来几年胃肠病学市场的成长。

目录

介绍

• 研究目的
• 调查范围
• 定义

调查方法

• 资讯采购
• 二手资料和主要资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 按细分市场的机会分析

市场动态及展望

• 市场概况
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 抑制因素和挑战
• 波特的分析

主要市场考察

• 关键成功因素
• 竞争程度
• 主要投资机会
• 市场生态系统
• 市场吸引力指数（2024年）
• PESTEL分析
• 总体经济指标
• 价值链分析
• 价格分析

胃肠病学市场规模：按类型

• 市场概况
• 品牌
• 非专利的

胃肠病学市场规模：依分销管道分类

• 市场概况
• 零售药房
• 医院药房
• 网路药房

胃肠病学市场规模：依应用分类

• 市场概况
• 克隆氏症
• 溃疡性大肠炎
• GERD
• IBS
• 其他的

胃肠病学市场规模：依给药途径分类

• 市场概况
• 可注射的
• 口头及其他

消化系统疾病市场规模

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地区
• 中东/非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东/非洲

竞争资讯

• 前5名企业对比
• 主要企业市场定位（2024年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市场占有率分析（2024年）
• 主要企业简介
  • 公司简介
  • 产品系列分析
  • 按细分市场分類的份额分析
  • 收益与前一年同期比较（2022-2024）

主要企业简介

• AbbVie Inc.（US）
• Takeda Pharmaceutical Company Limited（Japan）
• AstraZeneca plc（UK）
• Bayer AG（Germany）
• Pfizer Inc.（US）
• Johnson & Johnson（US）
• Novartis AG（Switzerland）
• Merck & Co., Inc.（US）
• Sanofi SA（France）
• GlaxoSmithKline plc（UK）
• Boehringer Ingelheim International GmbH（Germany）
• Teva Pharmaceutical Industries Limited（Israel）
• Boston Scientific Corporation（US）
• Medtronic plc（Ireland）
• Olympus Corporation（Japan）
• Fujifilm Corporation（Japan）
• Stryker Corporation（US）
• Nestle Health Science（Switzerland）
• Danone SA（France）

结论和建议

Global Gastroenterology Market size was valued at USD 37.4 billion in 2023 and is poised to grow from USD 62.65 billion in 2024 to USD 62.65 billion by 2032, growing at a CAGR of 5.9% during the forecast period (2025-2032).

The gastroenterology market is witnessing significant growth, driven by the increasing prevalence of gastrointestinal diseases, largely attributable to poor dietary habits and a growing elderly population. The surge in gastrointestinal disorders has led to a rise in hospitalizations and surgical interventions, prompting biopharmaceutical companies to intensify their R&D efforts in biologics and biosimilars. Additionally, the expansion of clinical trials, with 6,443 ongoing studies as of May 2021, indicates a robust pipeline for innovative treatments, including cellular therapies and small compounds. As the healthcare landscape evolves, these developments present new opportunities for effective therapies, further propelling the growth of the gastroenterology market in the coming years.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Gastroenterology market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Gastroenterology Market Segmental Analysis

Global Gastroenterology Market is segmented by type, distribution channel, application, route of administration and region. Based on type, the market is segmented into branded and generics. Based on distribution channel, the market is segmented into retail pharmacies, hospital pharmacies and online pharmacies. Based on application, the market is segmented into crohn's disease, ulcerative colitis, Gerd, IBS and others. Based on route of administration, the market is segmented into injectable and oral & others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Gastroenterology Market

The global gastroenterology market is being significantly influenced by the rising incidence of gastrointestinal diseases, such as gallstones, ulcerative colitis, hemorrhoids, and irritable bowel syndrome (IBS). Factors contributing to the increasing prevalence of both chronic and acute gastrointestinal conditions include unhealthy dietary choices, sedentary lifestyles, heightened stress levels, food sensitivities, and bacterial or viral infections. Consequently, there is a growing demand for various medications, including antacids, proton pump inhibitors, histamine H2-receptor antagonists, and antibiotics, to effectively manage these disorders and prevent related health complications. This surge in healthcare needs is propelling the expansion of the global market for gastroenterology therapeutics.

Restraints in the Global Gastroenterology Market

The global gastroenterology market is expected to encounter considerable challenges during the forecast period, primarily due to the escalating costs associated with treatments. Various gastrointestinal disorders, including chronic conditions like Crohn's disease and ulcerative colitis, require ongoing management to prevent recurrence and potential complications such as cancer. The comprehensive treatment expenses encompass medication costs, consultations, and hospital admissions, which significantly contribute to the overall financial burden. For instance, biologic therapies such as infliximab and vedolizumab can range from $6,000 to $8,700 per prescription, while monthly costs for some treatments can vary between $2,500 and $5,500. These increasing out-of-pocket expenses for treatments and procedures are likely to hinder the market's growth.

Market Trends of the Global Gastroenterology Market

The global gastroenterology market is poised for significant growth, fueled by the rising prevalence of gastrointestinal disorders like ulcerative colitis and Crohn's disease. Pharmaceutical and biotechnology companies are increasingly investing in research and development to innovate cutting-edge therapies, expanding their product pipelines to meet this growing demand. This trend is marked by a strong focus on developing revolutionary treatments that promise enhanced efficacy for patients. As both regional and global players ramp up their efforts in drug development, the global therapeutics market for gastrointestinal diseases is expected to thrive, presenting substantial opportunities for stakeholders over the forecast period.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Gastroenterology Market Size by Type & CAGR (2025-2032)

• Market Overview
• Branded
• Generics

Global Gastroenterology Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Retail Pharmacies
• Hospital Pharmacies
• Online Pharmacies

Global Gastroenterology Market Size by Application & CAGR (2025-2032)

• Market Overview
• Crohn's Disease
• Ulcerative Colitis
• Gerd
• IBS
• Others

Global Gastroenterology Market Size by Route Of Administration & CAGR (2025-2032)

• Market Overview
• Injectable
• Oral & Others

Global Gastroenterology Market Size & CAGR (2025-2032)

• North America (Type, Distribution Channel, Application, Route Of Administration)
  • US
  • Canada
• Europe (Type, Distribution Channel, Application, Route Of Administration)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Type, Distribution Channel, Application, Route Of Administration)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Type, Distribution Channel, Application, Route Of Administration)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Type, Distribution Channel, Application, Route Of Administration)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• AbbVie Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim International GmbH (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Limited (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boston Scientific Corporation (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Medtronic plc (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Olympus Corporation (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Fujifilm Corporation (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Stryker Corporation (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Nestle Health Science (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Danone S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations